ABSTRACT

AIM. To evaluate the expression level of microRNA-143 in patients with atherogenic acute cardiovascular diseases.

MATERIAL AND METHODS. A total of 133 patients with acute cardiovascular diseases of atherogenic etiology were examined. Group 1 included 81 patients diagnosed with ST-segment elevation myocardial infarction, and Group 2 included 52 patients diagnosed with atherothrombotic subtype of ischemic stroke in the carotid basin. The control group included 27 patients without a history of acute cardiovascular diseases. Upon hospitalization, all patients underwent examinations according to the standard of medical care for patients with stroke and acute coronary syndrome  with ST-segment elevation. The degree of stenosis of coronary and internal carotid artery was determined by coronary angiography/duplex scanning. The laboratory diagnostics included an assessment of lipidogram parameters at the time of patent admission. The level of microRNA-143 (miR-143) in blood plasma was determined by real-time PCR. For statistical data processing, standard software packages SPSS Statistics, as well as Pandas and SciPy libraries, were used.

RESULTS AND DISCUSSION. A higher level of LDL (p <0.0001) and a prevalence of occlusive atherosclerosis (p < 0.001, p < 0001) were revealed in patients of 1st group  compared to the 2nd and control groups; severe stenosis was found in patients of both main groups (p <0.0001, p = 0.0007) compared  to the control group with a predominance in patients of 1st group 1 (p = 0.001). Assessment of circulating miR-143 levels demonstrated a higher level of miR-143 (p <0.0001, p = 0.011) in patients of the main groups compared to the control group with a prevalence (p <0.0001) in patients of 1st group. The most significant correlation with the level of miR-143 was observed for LDL (r = 0.484) and the number of patients with severe atherosclerotic lesions of the coronary arteries (r = 0.454) in patients of 1st group, total cholesterol (r = 0.445), presence of diabetes mellitus (r = 0.418) and borderline atherosclerotic stenosis (r = 0.415) of the internal carotid artery - in patients of 2nd group.

CONCLUSION. The results of the study allow us to consider the level of miR-143 as one of the important regulators of the process of atherogenesis. The obtained results indicate the necessity to conduct multicenter studies with a larger sample size to determine the potential value of miR-143 as a biomarker of severity and course of acute cardiovascular diseases associated with stenosis of major arteries.

KEYWORDS: ischemic stroke, myocardial infarction, microRNA-143, atherosclerosis, cardiovascular diseases

For citation: Tynterova A.M., Mikhailova L.V., Tsapkova A.A., Vulf M.A., Litvinova L.S. MicroRNA-143 as a Biomarker of Atherogenic Acute Cardiovascular Diseases. Comorbidity Neurology. 2024; 1 (4): 12-19. https://doi.org/10.62505/3034-185x-2024-1-4-12-19

*For correspondence: Anastasya M. Tynterova, Cand. Sci. (Med.), Senior Researcher, Baltic Center for Artificial Intelligence and Neurotechnology, Imannuel Kant Baltic Federal University, Kaliningrad, Russia, e-mail: antynterova@mail.ru

REFERENCES

1.Boytsov S.A., Shakhnovich R.M., Erlikh A.D., Tereschenko S.N., Kukava N.G., Rytova Y.K. et al. Registry of Acute Myocardial Infarction. Kardiologiia. 2021; 61 (6): 41-51. https://doi.org/10.18087/cardio.2021.6.n1595 (In Russ.)

2.Klochikhina O.A., Shprach V.V., Stakhovskaya L.V., Polunina O.S, Polunina E.A. Dynamics of Stroke Morbidity and Mortality Over an Eight-Year Period in the Territories Included in the Federal Program for the Reorganization of care for Stroke Patients. Acta Biomedica Scientifica. 2021; 6 (1): 75-80. https://doi.org/10.29413/ ABS.2021-6.1.10. (In Russ.)

3.Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, Olaetxea JR, Alloza I, Vandenbroeck K et al. Pathophysiology of Atherosclerosis. Int J Mol Sci. 2022; 23 (6): 3346.  https://doi.org/10.3390/ijms23063346

4.Kramna D, Riedlova P, Jirik V. MicroRNAs as a Potential Biomarker in the Diagnosis of Cardiovascular Diseases. Medicina (Kaunas). 2023; 59 (7): 1329. https://doi.org/ 10.3390/medicina59071329

5.Gareev I.F., Beylerli O.A., Alyshov A.B. MicroRNA regulatory mechanisms in atherosclerosis. Herald of North-Western State Medical University named after I.I. Mechnikov. 2020; 12 (1): 11-20. https://doi.org/10.17816/mechnikov25898 (In Russ.)

6.Jiang Q, Li Y, Wu Q, Huang L, Xu J, Zeng Q. Pathogenic role of microRNAs in atherosclerotic ischemic stroke: Implications for diagnosis and therapy. Genes Dis. 2021; 9 (3): 682-696. https://doi.org/10.1016/j.gendis.2021.01.001

7.Bansal A, Prathap R, Gupta S, Chaurasia A, Chaudhary P. Role of microRNAs in stroke recovery. J Family Med Prim Care. 2019; 8 (6): 1850-1854.  https://doi.org/10.4103/jfmpc.jfmpc_296_19

8.Satake A, Minatoguchi S, Heishima K, Yasuda S, Murase H, Yoshizumi R, Komaki H, Baba S, Ojio S, Tanaka T, Akao Y, Minatoguchi S, Okura H. An Increase in Plasma MicroRNA-143 Levels in the Acute Phase Is Positively Correlated With Recovery of Cardiac Function in the Chronic Phase in Patients With Acute Myocardial Infarction. Circ J. 2023; 87 (6): 824-833. https://doi.org/10.1253/circj.CJ-22-0698

9.Aitbaev KA, Murkamilov IT, Fomin VV, et al. MicroRNA in ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2018; 118 (3‑2): 48‑56. https://doi.org/10.17116/jnevro20181183248-56 (In Russ.)

10. Zhao W., Zhao S.P., Zhao Y.H. MicroRNA-143/-145 in Cardiovascular Diseases. Biomed Res Int. 2015; 2015:531740. https://doi.org/10.1155/2015/531740

11.Graham A. Modulation of the Cellular microRNA Landscape: Contribution to the Protective Effects of High-Density Lipoproteins (HDL). Biology (Basel). 2023; 12 (9): 1232. https://doi.org/10.3390/biology12091232

12.Feinberg M.W., Moore K.J. MicroRNA Regulation of Atherosclerosis. Circ Res. 2016; 118 (4): 703-20. https://doi.org/10.1161/CIRCRESAHA.115.306300

13.Meng L., Yu X., Han H., Jia X., Hu B., Zhang L., Wang Z., Zhang W., Zhong M., Zhu H. Circulating miR-143 and miR-145 as promising biomarkers for evaluating severity of coronary artery stenosis in patients with acute coronary syndrome. Clin Biochem. 2023; 111: 32-40. https://doi.org/10.1016/j.clinbiochem.2022.10.004

14.Churov A., Summerhill V., Grechko A., Orekhova V., Orekhov A. MicroRNAs as Potential Biomarkers in Atherosclerosis. Int J Mol Sci. 2019; 20 (22): 5547.   https://doi.org/10.3390/ijms20225547

15.Sweet D.R., Fan L., Hsieh P.N., Jain M.K. Krüppel-Like Factors in Vascular Inflammation: Mechanistic Insights and Therapeutic Potential. Front Cardiovasc Med. 2018; 5: 6. https://doi.org/10.3389/fcvm.2018.00006

16.Turpaev K.T. Transcription Factor KLF2 and Its Role in the Regulation of Inflammatory Processes. Biochemistry (Mosc). 2020; 85 (1): 54-67. https://doi.org/10.1134/S0006297920010058

ADDITIONAL INFORMATION

Anastasya M. Tynterova, Cand. Sci. (Med.), Senior Researcher, Baltic Center for Artificial Intelligence and Neurotechnology, Imannuel Kant Baltic Federal University, Kaliningrad, Russia. E-mail:  antynterova@mail.ru. ORCID: https://orcid.org/0000-0003-1743-4713

Larisa V. Mikhailova, Cand. Sci. (Med.), Associate Professor, Head of the Department of Therapy of the Institute of Medicine and Life Sciences, Imannuel Kant Baltic Federal University, Kaliningrad, Russia. E-mail: mihalysa@mail.ru. ORCID: https://orcid.org/0000-0001-5070-5955

Alina A. Tsapkova, Clinical Pharmacologist of Clinical Trial Center, Imannuel Kant Baltic Federal University, Kaliningrad, Russia. E-mail: alina.tsapkova@inbox.ru. ORCID: https://orcid.org/0000-0002-2701-9719

Maria A. Vulf, Cand. Sci. (Biol.), Senior Research Officer at Center for Immunology and Cellular Biotechnology, Senior Lecturer of the Department of Fundamental Medicine of the Institute of Medicine and Life Sciences, Imannuel Kant Baltic Federal University, Kaliningrad, Russia. E-mail: mary-jean@yandex.ru. ORCID: https://orcid.org/0000-0002-4989-045X

Larisa S. Litvinova, Dr. Sci. (Med.), Professor, Director of the Center for Immunology and Cellular Biotechnologies, Imannuel Kant Baltic Federal University, Kaliningrad, Russia. E-mail: larisalitvinova@yandex.ru. ORCID: https://orcid.org/0000-0001-5231-6910

Author contributions. All authors confirm the compliance of their authorship, according to international ICMJE criteria (all authors made a significant contribution to the development of the concept, research and preparation of the article, read and approved the final version before publication). Tynterova A.M. – concept of the study, sampling of patients, drafting the text; Mikhailova L.V. – design of the study, sampling of patients, editing; Litvinova L.S. – scientific management; Vulf M.A. – statistical data processing; Tsapkova A.A. – material processing.

Funding. This work was performed within the scope of the of the "Priority 2030" program and State assignment FZWM-2024-0013 (Immanuel Kant Baltic Federal University).

Disclosure. The authors declare that they have no competing interests.

Ethics Approval. The study was approved by the Independent Ethics Committee of the Regional Clinical Hospital of the Kaliningrad region (protocol №2-23 of March 09, 2023) and the Independent Ethics Committee of the Center for Clinical Research of Imannuel Kant Baltic Federal University, (Kaliningrad, Russia) (Protocol № 2 of April 27, 2021).

Informed consent for publication. All patients, and if it is impossible to review and sign, persons responsible for the patients (relatives, social workers, etc.) on behalf of the patients undergoing examination and participating in this study, signed informed consent.

The content is available under the Creative Commons Attribution 4.0 License.

©2024. Anastasya M. Tynterova, Larisa V. Mikhailova, Alina A. Tsapkova et al.